



ATOPIC ECZEMA/DERMATITIS

BURDEN OF DISEASE AND UNMET NEEDS AMONG CHILDREN WITH MODERATE TO SEVERE ATOPIC DERMATITIS AND THEIR FAMILIES

Korey Capozza⁽¹⁾ - Alan Schwartz⁽²⁾

Global Parents For Eczema Research, N/a, Los Angeles, United States⁽¹⁾ - University Of Illinois, Chicago, Medical Education And Pediatrics, Chicago, United States⁽²⁾

Atopic Dermatitis (AD) is a chronic inflammatory skin disease that affects approximately 10% of children globally. The impact of pediatric moderate-severe atopic dermatitis on quality of life has been shown to exceed that of diabetes and asthma, and rival the impact of cerebral palsy. Anxiety, sleep deprivation, depression, profound discomfort, and difficulty functioning in school are just a few of the ways that moderate to severe AD manifests itself in the lives of children and their families. Recent studies have documented the adverse effects of AD on mental health and new evidence reveals associations with comorbid conditions like obesity and cardiovascular disease. Existing treatments have side effects that are concerning to parents, especially when used in small children. Yet the true impact of moderate to severe AD in childhood remains poorly understood. There is a strong need for input from patients and caregivers to adequately describe the burden of disease and to inform treatment regimens, future research and drug development.

In this patient-centered presentation we will highlight the results from a global survey of parents of children with moderate to severe AD and describe the burden of the condition and the unmet needs among young (pediatric) patients and their families. Further, we will communicate treatment, research and policy implications of the findings. Results are expected in February 2019.

